Pharmaceuticals and Medical Devices Agency (PMDA) Overview

The Pharmaceuticals and Medical Devices Agency (PMDA) is the Japanese regulatory agency that works together with the Ministry of Health, Labour and Welfare (MHLW). It is responsible for ensuring the safety, efficacy, and quality of pharmaceuticals and medical devices in Japan.

The Three Pillars of PMDA Services

The PMDA operates under a unique "safety triangle" framework known as the Three Services:

1. Relief Services for Adverse Health Effects: Providing compensation and medical benefits to patients who have suffered from adverse drug reactions or infections from biological products.
2. Reviews and Related Services: Conducting scientific reviews of marketing applications for drugs and medical devices, and performing audits of manufacturing facilities (GMP/QMS inspections).
3. Post-marketing Safety Measures: Collecting, analyzing, and disseminating information on the safety of products after they have entered the market to prevent further health damage.

Medical Device Classification in Japan

In Japan, medical devices are classified into four categories based on risk, following the GHTF (Global Harmonization Task Force) framework:

• Class I (General Medical Devices): Extremely low risk (e.g., surgical knives, X-ray film).
• Class II (Controlled Medical Devices): Low risk (e.g., MRI equipment, electronic thermometers).
• Class III (Highly Controlled Medical Devices): Medium risk (e.g., artificial joints, dialyzers).
• Class IV (Highly Controlled Medical Devices): High risk / Life-threatening risk (e.g., pacemakers, artificial heart valves).

The Regulatory Path to Market

The approval process generally involves:

1. Application: Submitted to the PMDA.
2. Review: The PMDA conducts a technical review and QMS (Quality Management System) inspection.
3. Approval: Based on the PMDA's review report, the MHLW grants the final marketing authorization.
4. Post-Market: Ongoing surveillance and safety reporting managed by the PMDA.